OBJECTIVE: To describe the use and frequency of injection of OZURDEX in the treatment of adult patients with macular oedema following a branch retinal vein occlusion, (BRVO) or central retinal vein occlusion (CRVO).

METHODS: An observational, retrospective, non-interventional, multi-centre study of patients receiving intravitreal injections of Ozurdex for BRVO and CRVO between January 1st and December 31st 2012. A total of 32 ophthalmologists participated (53% working in public practice and 47% in private practice), reporting the treatment of 546 patients. All ophthalmologists were based in France and are required to remain anonymous to Allergan. Registered ophthalmologists were contacted telephonically and offered the choice of collecting the information via internet or paper. Responses were only obtained for Ozurdex only treated patients with macular edema following BRVO or CRVO.

RESULTS: A total of 546 patients with a mean age of 71.2 were studied; distributed between 51% male and 49% female. 57% presented BRVO and 43% CRVO. 827 injections were performed in 546 patients, with an average of injection per eye per patient of 1.5 (CI 95% 1.43 – 1.57) per year; 1 injection in 53%, 2 in 41%, 3 in 5% and 4 in 1% of the total number of patients.

CONCLUSIONS: The results are consistent with previous publications in terms of the average of injection per year. And less than the 1.8 injections per year assessed in the GENEVA trial. Supporting the expected injection frequency of less than 1.8 injections per year.

Finance Disclosure: M. Velard and O. Mesa are employees of Allergan